Uterine Fibroid Trials, Fertility Safety, GnRH and Focal Adenomyosis

Uterine Fibroids The FDA approved ExAblate 2000 for the treatment of uterine fibroids in October 2004. Since then InSightec has conducted additional continued access studies using expanded treatment guidelines and continues to collect this data on these patients for up to 36 months follow-up. InSightec reports this data every six months to the FDA. InSightec is also conducting studies to expand indications for additional uterine fibroids patients. Click here to read the latest FDA summary report. Click here to visit our patient website.

Fertility Enhancement Study

This trial is for patients with symptomatic uterine fibroids who would like to become pregnant after undergoing MRgFUS treatment. A follow-up regimen applies and patients must meet inclusion and exclusion criteria for eligibility in this study. This trial is being conducted only outside the USA. Click here to find a list of participating hospitals.

Focal Adenomyosis

This study is intended for women who are suffering from adenomyosis. This study is being conducted only outside the USA. Click here to find the list of participating hospitals.

Enhanced Treatment Study

This is an enhanced treatment study for validating new features of the ExAblate system. Click here to find the list of participating hospitals.

Back to list